| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1464-410X.1999.00251.X |
| P698 | PubMed publication ID | 10510109 |
| P2093 | author name string | Madersbacher H | |
| Alloussi S | |||
| Voigt R | |||
| Halaska M | |||
| Höfner K | |||
| P2860 | cites work | Evaluation of three methods of symptom reporting in a clinical trial of felodipine | Q44643585 |
| P433 | issue | 6 | |
| P921 | main subject | patient | Q181600 |
| placebo | Q269829 | ||
| P304 | page(s) | 646-651 | |
| P577 | publication date | 1999-10-01 | |
| P1433 | published in | BJU International | Q4835773 |
| P1476 | title | A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. | |
| P478 | volume | 84 |
| Q37653402 | A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. |
| Q35115410 | A comparison of three methods to evaluate maximum bladder capacity: cystometry, uroflowmetry and a 24‐h voiding diary in women with urinary incontinence |
| Q36552209 | A meta-analysis comparing trials of antimuscarinic medications funded by industry or not. |
| Q33485538 | A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder |
| Q30483622 | Actions of two main metabolites of propiverine (M-1 and M-2) on voltage-dependent L-type Ca2+ currents and Ca2+ transients in murine urinary bladder myocytes |
| Q28742444 | Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach |
| Q35042575 | An overview of the clinical use of antimuscarinics in the treatment of overactive bladder |
| Q38024986 | An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity |
| Q24243870 | Anticholinergic drugs versus placebo for overactive bladder syndrome in adults |
| Q34758373 | Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. |
| Q36574048 | Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? |
| Q36565377 | Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures |
| Q37428717 | Basic mechanisms of urgency: roles and benefits of pharmacotherapy |
| Q44795031 | Behavioral and drug therapy for urinary incontinence |
| Q28201946 | Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies |
| Q40963346 | Clinical Guideline for Female Lower Urinary Tract Symptoms |
| Q46116817 | Clinical guidelines for overactive bladder |
| Q35200049 | Clinical pharmacology of old age syndromes |
| Q35419834 | Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study) |
| Q37582301 | Considerations for the management of urgency symptoms in patients with overactive bladder syndrome |
| Q58257460 | Continence, incontinence and the aging male |
| Q80363820 | Cost Effectiveness of Controlled-Release Oxybutynin Compared with Immediate-Release Oxybutynin and Tolterodine in the Treatment of Overactive Bladder in the UK, France and Austria |
| Q36428481 | Cost implications of antimuscarinic drugs in the treatment of overactive bladder syndrome |
| Q35219131 | Drug effects on salivary glands: dry mouth |
| Q35838373 | Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. |
| Q36833843 | Efficacy and tolerability of combined medication of two different antimuscarinics for treatment of adults with idiopathic overactive bladder in whom a single agent antimuscarinic therapy failed |
| Q43225326 | Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study |
| Q48182944 | Excitatory effect of propiverine hydrochloride on urethral activity in rats |
| Q51856626 | Guidelines for management of urinary incontinence. |
| Q44289975 | In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats |
| Q46855055 | In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder |
| Q34285907 | Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor |
| Q44322955 | K-ATP opener-mediated attenuation of spontaneous bladder contractions in ligature-intact, partial bladder outlet obstructed rats |
| Q38811069 | Managing Disability in Progressive Multiple Sclerosis |
| Q45194161 | Medical therapy of urinary incontinence |
| Q81640042 | Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination |
| Q36779724 | Overactive bladder syndrome in older people |
| Q44507241 | Overactive bladder--treatment with antimuscarinic agents |
| Q44507238 | Overactive bladder--which diagnosis investigations are necessary before initiating primary treatment? |
| Q35166777 | Oxybutynin: an overview of the available formulations |
| Q57261042 | Pediatric overactive bladder and lower urinary tract dysfunctions: diagnosis and treatment |
| Q37021231 | Pediatric overactive bladder syndrome: pathophysiology and management |
| Q37864717 | Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature |
| Q46816221 | Pharmacological effects of propiverine and its active metabolite, M-1, on isolated human urinary bladder smooth muscle, and on bladder contraction in rats |
| Q82574887 | Pharmacotherapy of urinary incontinence |
| Q57307280 | Posterior tibial nerve stimulation in the treatment of urge incontinence |
| Q38071594 | Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms |
| Q50907877 | Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder. |
| Q36219834 | Role of muscarinic receptor antagonists in urgency and nocturia |
| Q36655193 | Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder |
| Q36565383 | The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis |
| Q37836943 | The medical treatment of overactive bladder, including current and future treatments. |
| Q36428471 | The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy |
| Q34197411 | The placebo effect in overactive bladder syndrome |
| Q36023698 | The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects |
| Q49150455 | The therapeutic effect of solifenacin succinate on the recovery from voiding dysfunction after radical prostatectomy in men with clinically localized prostate cancer: a prospective, randomized, controlled study |
| Q46694169 | Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials |
| Q33515909 | Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. |
| Q44004624 | Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women |
| Q46906921 | Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis |
| Q24203880 | Which anticholinergic drug for overactive bladder symptoms in adults |
| Q24246651 | Which anticholinergic drug for overactive bladder symptoms in adults |
| Q81491451 | [Therapy for overactive detrusor using propiverine] |
| Q84511392 | [Therapy of overactive bladder with propiverine ER: results of a non-interventional study with a propiverine retard formulation and comparison to clinical studies] |
| Q35183611 | α1-Adrenoceptors and muscarinic receptors in voiding function - binding characteristics of therapeutic agents in relation to the pharmacokinetics |
Search more.